Skip to main content
BioCardia, Inc. logo

BioCardia, Inc. — Investor Relations & Filings

Ticker · BCDA ISIN · US09060U5074 LEI · 5493003EDBXRQRW22O75 US Manufacturing
Open in API
Filings indexed 1,023 across all filing types
Latest filing 2020-02-26 Director's Dealing
Country US United States of America
Listing US BCDA

About BioCardia, Inc.

https://www.biocardia.com/

BioCardia, Inc. is a clinical-stage regenerative medicine company that develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases. The company's lead program is the CardiAMP® cell therapy system, an autologous therapy that uses a patient's own bone marrow cells to potentially stimulate the body's natural healing response in the heart. This therapy is primarily being evaluated for the treatment of ischemic heart failure. In addition to its autologous platform, BioCardia is also developing CardiALLO™, an allogeneic cell therapy platform using cells from qualified donors. The company's approach integrates biotherapeutic candidates with proprietary delivery systems for targeted administration.

Recent filings

Filing Released Lang Actions
FORM 3
Director's Dealing
2020-02-26 English
Regulatory Filings 2020
Regulatory Filings Classification · 90% confidence The provided document text appears to be an encoded or corrupted file content rather than readable text. There are no discernible keywords, regulatory references, fiscal period dates, or document titles that indicate the nature of the filing. The length is about 15,000 characters, but the content does not contain any meaningful financial or corporate information. Given the lack of identifiable information and the fallback rule, the document should be classified as a Regulatory Filing (RNS).
2020-02-20 English
FORM S-8
Share Issue/Capital Change Classification · 95% confidence The document is a Form S-8 Registration Statement filed with the SEC, which is used to register securities to be offered under employee benefit plans such as equity incentive plans. The text includes details about the number of shares registered, the equity incentive plan, incorporation by reference of prior filings, and legal indemnification provisions. It is not a financial report, earnings release, or management discussion, but a registration statement related to share issuance under an equity plan. This matches the category of Share Issue/Capital Change (SHA), which covers announcements regarding new share issues or capital changes. The document length and content confirm it is the registration statement itself, not just an announcement or a certification. Therefore, the correct classification is SHA with high confidence.
2020-02-12 English
FORM S-1
Capital/Financing Update Classification · 95% confidence The document is a Form S-1 Registration Statement filed with the SEC, which is used by companies to register securities for public offering under the Securities Act of 1933. It includes detailed information about the company, the offering, risk factors, use of proceeds, business description, management discussion and analysis, executive compensation, and other disclosures typical of a registration statement prospectus. This is not an annual report, earnings release, or any other type of financial report but a capital raising filing. Therefore, it fits the category of Capital/Financing Update (CAP). The document length is substantial (15,000 characters), and it is the actual registration statement, not just an announcement of it, so it is not RPA or RNS. Hence, the correct classification is CAP with high confidence.
2020-02-12 English
FORM 4
Director's Dealing
2020-02-10 English
FORM 4
Director's Dealing
2020-02-10 English

Browse filings by year

24 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.